Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

Jorge Cortes, Patricia Ault, Charles Koller, Deborah Thomas, Alessandra Ferrajoli, William Wierda, Mary B. Rios, Laurie Letvak, Elizabeth S. Kaled, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent eosinophilia and organ involvement. Different treatments have been investigated in HES with modest success. It has been suggested that imatinib is active in HES. We treated 9 patients with HES with 100 mg imatinib daily. Doses for patients without response after 4 weeks were increased to 400 mg daily. Prior therapy had failed for 7 patients. Five patients responded: 4 achieved sustained complete remission lasting a median of 12+ weeks (range, 9+ to 36+ weeks), and 1 had a transient response. One patient died in complete remission. Responses occurred within 4 weeks of therapy; only 1 responder required an increase in dose to 400 mg daily. Three of 4 nonresponders failed to respond to an increase in dose. Toxicity was minimal. We conclude that imatinib therapy is effective for HES.

Original languageEnglish (US)
Pages (from-to)4714-4716
Number of pages3
JournalBlood
Volume101
Issue number12
StatePublished - Jun 15 2003
Externally publishedYes

Fingerprint

Hypereosinophilic Syndrome
Transient analysis
Toxicity
Therapeutics
Myeloproliferative Disorders
Eosinophilia
Imatinib Mesylate

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Cortes, J., Ault, P., Koller, C., Thomas, D., Ferrajoli, A., Wierda, W., ... Kantarjian, H. (2003). Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood, 101(12), 4714-4716.

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. / Cortes, Jorge; Ault, Patricia; Koller, Charles; Thomas, Deborah; Ferrajoli, Alessandra; Wierda, William; Rios, Mary B.; Letvak, Laurie; Kaled, Elizabeth S.; Kantarjian, Hagop.

In: Blood, Vol. 101, No. 12, 15.06.2003, p. 4714-4716.

Research output: Contribution to journalArticle

Cortes, J, Ault, P, Koller, C, Thomas, D, Ferrajoli, A, Wierda, W, Rios, MB, Letvak, L, Kaled, ES & Kantarjian, H 2003, 'Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome', Blood, vol. 101, no. 12, pp. 4714-4716.
Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003 Jun 15;101(12):4714-4716.
Cortes, Jorge ; Ault, Patricia ; Koller, Charles ; Thomas, Deborah ; Ferrajoli, Alessandra ; Wierda, William ; Rios, Mary B. ; Letvak, Laurie ; Kaled, Elizabeth S. ; Kantarjian, Hagop. / Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. In: Blood. 2003 ; Vol. 101, No. 12. pp. 4714-4716.
@article{e64dd8e8e84d46749beaa60cf38c61e9,
title = "Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome",
abstract = "Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent eosinophilia and organ involvement. Different treatments have been investigated in HES with modest success. It has been suggested that imatinib is active in HES. We treated 9 patients with HES with 100 mg imatinib daily. Doses for patients without response after 4 weeks were increased to 400 mg daily. Prior therapy had failed for 7 patients. Five patients responded: 4 achieved sustained complete remission lasting a median of 12+ weeks (range, 9+ to 36+ weeks), and 1 had a transient response. One patient died in complete remission. Responses occurred within 4 weeks of therapy; only 1 responder required an increase in dose to 400 mg daily. Three of 4 nonresponders failed to respond to an increase in dose. Toxicity was minimal. We conclude that imatinib therapy is effective for HES.",
author = "Jorge Cortes and Patricia Ault and Charles Koller and Deborah Thomas and Alessandra Ferrajoli and William Wierda and Rios, {Mary B.} and Laurie Letvak and Kaled, {Elizabeth S.} and Hagop Kantarjian",
year = "2003",
month = "6",
day = "15",
language = "English (US)",
volume = "101",
pages = "4714--4716",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

AU - Cortes, Jorge

AU - Ault, Patricia

AU - Koller, Charles

AU - Thomas, Deborah

AU - Ferrajoli, Alessandra

AU - Wierda, William

AU - Rios, Mary B.

AU - Letvak, Laurie

AU - Kaled, Elizabeth S.

AU - Kantarjian, Hagop

PY - 2003/6/15

Y1 - 2003/6/15

N2 - Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent eosinophilia and organ involvement. Different treatments have been investigated in HES with modest success. It has been suggested that imatinib is active in HES. We treated 9 patients with HES with 100 mg imatinib daily. Doses for patients without response after 4 weeks were increased to 400 mg daily. Prior therapy had failed for 7 patients. Five patients responded: 4 achieved sustained complete remission lasting a median of 12+ weeks (range, 9+ to 36+ weeks), and 1 had a transient response. One patient died in complete remission. Responses occurred within 4 weeks of therapy; only 1 responder required an increase in dose to 400 mg daily. Three of 4 nonresponders failed to respond to an increase in dose. Toxicity was minimal. We conclude that imatinib therapy is effective for HES.

AB - Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent eosinophilia and organ involvement. Different treatments have been investigated in HES with modest success. It has been suggested that imatinib is active in HES. We treated 9 patients with HES with 100 mg imatinib daily. Doses for patients without response after 4 weeks were increased to 400 mg daily. Prior therapy had failed for 7 patients. Five patients responded: 4 achieved sustained complete remission lasting a median of 12+ weeks (range, 9+ to 36+ weeks), and 1 had a transient response. One patient died in complete remission. Responses occurred within 4 weeks of therapy; only 1 responder required an increase in dose to 400 mg daily. Three of 4 nonresponders failed to respond to an increase in dose. Toxicity was minimal. We conclude that imatinib therapy is effective for HES.

UR - http://www.scopus.com/inward/record.url?scp=10744228476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228476&partnerID=8YFLogxK

M3 - Article

C2 - 12595304

AN - SCOPUS:10744228476

VL - 101

SP - 4714

EP - 4716

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -